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1. Introduction 
 Erythropoietin (Epo) is generally one of the more well 
studied growth factors. Epo implicates over 28,595 known 
biomedical studies at present. 3.39% at least of these studies concern 
tissue ischemia and reperfusion (IR) experiments. Certainly, 
important progress has been made concerning the Epo usage in 
reversing the IR kind of transient or permanent injuries including 
adjacent organs and certainly patients’ health. Nevertheless, 
satisfactory answers have not been provided yet to basic questions, 
as, its action velocity, the administration timing and the dosage. The 
concept is to forward the knowledge away from the original action of 
Epo in stem blood cells recovery. However, just few related reports 
were found, not covering completely more specific matters. A 
numeric evaluation of the Epo efficacy was yielded by a meta-analysis 
of 25 published seric variables, based on the same experimental 
setting, at the same endpoints (Table 1).  
 
Table 1: The erythropoietin (Epo) influence (+SD) on the levels of some seric[1] variables concerning reperfusion (rep) time 
Variable 1h rep 
p-
value 
1.5h rep 
p-
value 
2h rep 
p-
value 
interaction of Epo 
and rep 
p-
value 
White BCC          +24.01%+13.38% 0.1012 +22.09%+9.11% 0.0163 +20.17%+12.94% 0.0902 +14.63%+5.40% 0.0080 
Red BCC +1.45%+3.31% 0.6589 +0.37%+3.02% 0.9048 -0.70%+4.68% 0.8844 +0.81%+1.79% 0.6446 
Hematocrit +0.14%+2.89% 0.9626 -0.61%+2.37% 0.8072 -1.37%+4.05% 0.7485 +0.24%+1.38% 0.8586 
MCH +0.01%+1.29% 0.9904 +0.67%+0.80% 0.3549 +1.34%+1.08% 0.1509 -0.36%+0.47% 0.4430 
RbcDW -1.85%+4.24% 0.6703 -1.64%+2.53% 0.5159 -1.43%+3.34% 0.6078 -1.06%+1.43% 0.4733 
Platelet DW +1.60%+0.80% 0.0765 +1.36%+0.58% 0.0205 +1.13%+0.74% 0.1152 +0.37%+0.37% 0.0615 
Platelet-crit -16.47%+10.40% 0.0921 -13.74%+7.01% 0.0158 -11.01%+7.34% 0.0882 -6.88%+3.69% 0.0615 
Urea +21.42%+7.84% 0.0115 +20.11%+7.25% 0.0059 +18.80%+9.44% 0.0709 +15.64%+4.04% 0.0003 
Creatinine -0.10%+9.78% 0.9904 -4.84%+5.78% 0.3721 -9.59%+7.74% 0.1509 -2.62%+3.49% 0.4430 
Uric acid                        +10.13%+15.10% 0.4917 +15.86%+10.21% 0.1408 +21.59%+15.45% 0.1940 +9.33%+6.16% 0.1264 
Total protei                -0.02%+2.47% 0.9904 -1.27%+1.51% 0.3721 -2.52%+2.03% 0.1509 -0.68%+2.48% 0.4430 
Albumins2 -4.61%+4.21% 0.2530 -9.28%+3.20% 0.0054 -13.96%+5.03% 0.0095 -5.37%+2.73% 0.0072 
ALT +18.89%+12.42% 0.1372 +7.63%+18.94% 0.6396 -3.63%+25.19% 0.8617 +8.03%+11.36% 0.4698 
γGT -19.35%+18.58% 0.2362 -12.70%+13.11% 0.3541 -6.06%+19.96% 0.7800 -4.62%+7.97% 0.5534 
ALP   +0.20%+18.57% 0.9904 +10.70%+12.78% 0.3549 +21.20%+17.11% 0.1509 +5.79%+7.72% 0.4430 
ACP          +0.06%+5.79% 0.9904 +3.11%+3.71% 0.3172 +6.16%+4.97% 0.1509 +1.68%+2.23% 0.4430 
CPK +0.15%+14.09% 0.9904 +7.91%+9.44% 0.3549 +15.67%+12.65% 0.1509 +4.28%+5.70% 0.4430 
LDH +0.08%+7.92% 0.9904 +4.48%+5.35% 0.3549 +8.89%+7.17% 0.1509 +2.42%+3.22% 0.4430 
Sodium +0.72%+0.74% 0.3054 +0.21%+0.63% 0.7136 -0.29%+1.09% 0.7670 -0.11%+0.38% 0.7531 
Potassium -6.17%+4.94% 0.1540 -2.21%+3.66% 0.5134 +1.74%+5.43% 0.7299 +0.18%+2.22% 0.9338 
Calcium1 0.28%+1.19% 0.8065 -0.56%+1.13% 0.5761 -1.41%+2.08% 0.4100 -0.34%+0.68% 0.6095 
Phosphorus +1.92%+5.25% 0.6982 +3.95%+3.35% 0.2100 +5.98%+4.81% 0.2930 +2.45%+2.01% 0.2168 
Magnesium +1%+6.20% 0.8596 -1.09%+3.34% 0.7248 -3.19%+3.90% 0.3729 -0.19%+1.93% 0.9197 
Amylase +6.50%+9.15% 0.4161 +5.04%+6.12% 0.3831 +3.59%+8.42% 0.6649 +4.36%+3.65% 0.2258 
Progesteron -0.20%+18.65% 0.9904 -8.86%+10.58% 0.3549 -17.53%+14.15% 0.1509 -4.79%+6.39% 0.4430 
Μean +1.59%+9.55% 0.5941 +1.86%+8.93% 0.3753 +2.14%+10.73% 0.3558 +1.72%+5.59% 0.4186 
Abstract 
Objective: This experimental study examined the effect of erythropoietin (Epo) in rat 
model and particularly in an ischemia-reperfusion (IR) protocol. The effect of that 
molecule was studied biochemically using blood mean creatine kinase MB (CK-MB) levels.  
Materials and methods: 40 rats of mean weight 247.7 g were used in the study. CK-MB 
levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of 
reperfusion. Erythropoietin was administered only in groups C and D. 
Results: Erythropoietin administration kept non significantly increased the predicted CK-
MB values by 4.28%+5.11% (P= 0.3721). Reperfusion time non significantly decreased the 
predicted CK-MB values by the same quantities 4.28%+5.11% (P= 0.3721). Interaction of 
erythropoietin administration and reperfusion time kept non significantly increased the 
predicted CK-MB values by 2.32%+3.09% (P= 0.4430).  
Conclusions: Erythropoietin administration whether it interacted or not with reperfusion 
time kept short-term non significantly increased the predicted CK-MB values.  
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 The special aim of this experimental work was to study the 
effect of Epo on a rat model and mainly in an IR protocol. The effect of 
Epo molecule was tested by measuring the blood mean creatine 
kinase MB (CK-MB) levels. 
2. Materials and Methods 
2.1. Animal preparation 
Prefectural veterinary Address of East Attiki licensed the 
experiment under 3693/12-11-2010 & 14/10-1-2012 decisions. All 
substances, equipment and consumable needed for the study was a 
courtesy of ELPEN Pharmaceuticals Co Inc. S.A. at Pikermi, Attiki. 
Formal human animal care was adopted for female albino Wistar 
rats. Normal 7 days pre-experimental housing in laboratory included 
ad libitum diet. Prenarcosis of animals, preceded of continuous intra-
experimental general anesthesia [1-2], electrocardiogram, 
acidometry and oxygen supply. Post-experimental preservation of 
the rodents was not permitted even if euthanasia was required. 
The rodents were randomly delivered to four experimental 
groups, each one consisted by 10 animals. The 4 groups had common 
the stage of preceded ischemia of 45 min induced by laparotomic 
forceps clamping inferior aorta over renal arteries. Afterwards, 
reperfusion was restored by removing the clamp and 
reestablishment of inferior aorta patency. Reperfusion of 60 min was 
followed for group A. Reperfusion of 120 min was followed for group 
B. Immediate Epo intravenous (IV) administration and reperfusion of 
60 min was followed for group C. Immediate Epo IV administration 
and reperfusion of 120 min was followed for group D. The dosage for 
molecule Epo was 10 mg/kg body mass per animal. Epo 
administration was performed at the time of reperfusion, through 
catheterized inferior vena cava. The CK-MB levels evaluations were 
performed at 60 min of reperfusion for A and C groups and at 120 
min of reperfusion for B and D groups. The mean mass of the forty 
(40) female Wistar albino rats used was 247.7 g [Standard Deviation 
(SD): 34.99172 g], min weight 165 g and max weight 320 g. Rats' 
mass could be probably a confusing factor, e.g. the more obese rats to 
have higher CK-MB levels. This assumption was also investigated. 
2.2 Model of ischemia-reperfusion injury 
Control groups: 20 control rats (mean mass 252.5 g [SD: 39.31988 
g]) experienced ischemia for 45 min followed by reperfusion.  
Group A: Reperfusion lasted for 60 min (n=10 controls rats) mean 
mass 243 g [SD: 45.77724 g], mean CK-MB levels 299.4 IU/L [SD: 
176.6592 IU/L] (Table 2).     
Group B: Reperfusion lasted for 120 min (n=10 controls rats) mean 
mass 262 g [SD: 31.10913 g], mean CK-MB levels 315 IU/L [SD: 
189.6535 IU/L] (Table 2).   
Erythropoietin group: 20 Epo rats (mean mass 242.9 g [SD: 30.3105 
g] experienced ischemia for 45 min followed by reperfusion in the 
beginning of which 10 mg Epo /kg body weight were IV 
administered.  
Group C: Reperfusion lasted for 60 min (n=10 Epo rats) mean mass 
242.8 g [SD: 29.33636 g], mean CK-MB levels 454.9 IU/L [SD: 
126.1326 IU/L] (Table 2).     
Group D: Reperfusion lasted for 120 min (n=10 Epo rats) mean mass 
243 g [SD: 32.84644 g], mean CK-MB levels 429.7 IU/L [SD: 161.9678 
IU/L] (Table 2). 
Table 2: Weight and CK-MB mean levels and Std. Dev. of groups 
Groups   Variable Mean Std. Dev 
Α Weight 243 g                                        45.77724 g 
CK-MB                                    299.4 IU/L                             176.6592 IU/L 
B   Weight 262 g                                         31.10913 g 
CK-MB 315 IU/L                                   189.6535 IU/L 
C Weight 242.8 g 29.33636 g 
CK-MB 454.9 IU/L 126.1326 IU/L 
D Weight 243 g 32.84644 g 
CK-MB                                    429.7 IU/L                             161.9678 IU/L 
2.3 Statistical analysis  
Every weight and CK-MB level group was compared with 
each other from 3 remained groups applying respective statistical 
standard t-tests (Table 3). If any probable significant difference 
among CK-MB levels was raised, it would be investigated whether 
owed in any respective probable significant mass one (Table 3). 
Then, the application of generalized linear models (glm) was 
followed. It included as dependant variable the CK-MB levels. The 3 
independent variables were the Epo administration or no, the 
reperfusion time and their interaction. Inserting the rats’ mass as 
independent variable at glm, a significant correlation appeared with 
CK-MB levels (p= 0.0368), so as to further investigation was needed. 
The predicted CK-MB values, adjusted for rats’ weight were 
calculated and are depicted at table 5. Afterwards, every predicted 
CK-MB level group was compared with each other from 3 remained 
groups applying respective statistical standard t-tests (Table 6). 
Then, a second application of generalized linear models (glm) was 
followed. It included as dependant variable the predicted CK-MB 
levels. The 3 independent variables were again the Epo 
administration or no, the reperfusion time and their interaction. The 
statistical analysis was performed by Stata 6.0 software [Stata 6.0, 
StataCorp LP, Texas, USA].  
3. Results 
The first glm resulted in: Epo administration kept 
significantly increased the CK-MB levels by 135.1 IU/L [31.86157 
IU/L - 238.3384 IU/L] (P= 0.0117). This finding was in accordance 
with the results of standard t-test (p=0.0078). Reperfusion time non-
significantly decreased the CK-MB levels by 4.8 IU/L [-117.157 IU/L - 
107.557 IU/L] (P= 0.9315), in accordance also with standard t-test 
(P= 0.8944). However, erythropoietin administration and 
reperfusion time together produced a significant combined effect in 
keeping increased the CK-MB levels by 69.10909 IU/L [5.262361 
IU/L - 132.9558 IU/L] (P= 0.0346). Reviewing the above and table 3, 
the tables 4 and 5 sum up concerning the alteration influence of Epo 
in connection with reperfusion time. The second glm application 
resulted in: Erythropoietin administration kept non significantly 
increased the predicted CK-MB values by 15.74619 IU/L [-21.11541 
IU/L - 52.60779 IU/L] (P= 0.3926), in accordance also with standard 
t-test (P= 0.3517). Reperfusion time non significantly decreased the 
predicted CK-MB values by 15.74622 IU/L [-52.60782 IU/L - 
21.11539 IU/L] (P= 0.3926), in accordance also with standard t-test 
(P= 0.3517). Interaction of erythropoietin administration and 
reperfusion time kept non significantly increased the predicted CK-
MB values by 8.529186 IU/L [-13.7414 IU/L - 30.79977 IU /L] (P= 
0.4430). Reviewing the above and table 6, the tables 7 and 8 sum up 
concerning the alteration influence of Epo in connection with 
reperfusion time.  
Table 3: Statistical significance of mean values difference for 
groups (DG) after statistical standard t test application. 
DG Variable Difference p-value 
Α-Β Weight -19 g 0.2423 
CK-MB -15.6 IU/L 0.7558 
Α-C Weight 0.2 g 0.9900 
CK-MB -155.5 IU/L 0.0344 
Α-D Weight 0 g 1.0000 
CK-MB -130.3 IU/L 0.0574 
Β-C Weight 19.2 g 0.2598 
CK-MB -139.9 IU/L 0.0813 
Β-D Weight 19 g 0.1011 
CK-MB -114.7 IU/L 0.1294 
C-D Weight -0.2 g 0.9883 
CK-MB 25.2 IU/L 0.6519 
Table 4: The restorative influence of erythropoietin in 
connection with reperfusion time 
                                   p-values 
Increase 95% c. in. Reperfusion 
time 
t-test glm 
155.5 IU/L        11.28747 IU/L - 
299.7125 IU/L 
1h 0.0344               0.0361   
135.1 IU/L       31.86157 IU/L - 
238.3384 IU/L 
1.5h 0.0078 0.0117    
114.7 IU/L -50.99605 IU/L - 
280.396 IU/L 
2h 0.1294              0.1631       
-4.8 IU/L            117.157 IU/L - 
107.557 IU/L     
-reperfusion 
time              
0.8944               0.9315 
69.10909 
IU/L   
5.262361 IU/L - 
132.9558 IU/L             
interaction                                           0.0346 
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Table 5: Mean predicted CK-MB values adjusted for weight and 
Std. Dev. of groups 
Groups Mean                                         Std. Dev    
A 382.4591 IU/L 75.08527 IU/L 
B 351.2947 IU/L 51.02618 IU/L 
C 382.7871 IU/L                                48.11842 IU/L    
D 382.4591 IU/L                                53.87576 IU/L 
Table 6: Statistical significance of mean values difference for 
groups (DG) after statistical standard t test application 
DG Difference p-value 
Α-Β 31.16439 IU/L 0.2423 
Α-C -0.3280151 IU/L 0.9900 
Α-D                                               0.0000275 IU/L 1.0000 
Β-C                                                -31.4924 IU/L 0.2598 
Β-D                                               -31.16436 IU/L 0.1011 
C-D 0.3280426 IU/L 0.9883 
Table 7: The restorative influence of erythropoietin in 
connection with reperfusion time 
    p-values 
Increase 95% c. in Reperfusion 
time 
t-test           glm 
0.3280151 
IU/L     
-58.9209 IU/L - 
59.57693 IU/L 
1h 0.9900 0.9908   
15.74618755 
IU/L 
-21.11541 IU/L - 
52.60779 IU/L        
1.5h                   0.3517 0.3926 
31.16436 IU/L -18.1347 IU/L - 
80.46342 IU/L 
2h 0.1011 0.2007       
-15.74622 
IU/L    
-52.60782 IU/L -  
21.11539 IU/L    
reperfusion 
time      
0.3517           0.3926 
8.529186 IU/L       -13.7414 IU/L - 
30.79977 IU /L   
interaction    0.4430 
Table 8: The (%) restorative influence of erythropoietin in 
connection with reperfusion time 
Increase +SD                                   Reperfusion time                  p-values   
0.08%                          +7.90%                                              1h 0.9904   
4.28% +5.11% 1.5h                           0.3721                                           
8.49%                          +6.85%                                              2h 0.1509       
-4.28%                         +5.11% reperfusion time                  0.3721 
2.32%                          +3.09%                                       interaction 0.4430 
 
4. Discussion 
Many clinical situations can prove how CK-MB levels are 
influenced by ischemic cases. Gonçalves et al noted [3] a significant 
increase in plasma CK-MB levels after 30 minutes IR in control rats 
than treated ones by ornithine α-ketoglutarate. Jebeli et al [4] found 
significantly higher CK-MB serum levels in myocardial ischemia or 
infarction patients with impaired left ventricular function [(LVEF) < 
35%] undergoing on-pump coronary artery bypass graft (CABG) 
treated by placebo than treated by milrinone (50.5 μg/kg/min) (p < 
0.05). Sala et al [5] found more frequent by 3.95-fold the CK-MB peak 
levels > 300 IU/L in patients with acute phase of myocardial 
infarction (AMI), suffered from ventricular tachycardia (VT) in 
coronary care unit. Serruys et al [6] foundno instances of CK-MB 
levels elevations 10 or more times the upper limit of normal in 
patients after successful completion of their first percutaneous 
coronary intervention PCI randomly receiving treatment with 
fluvastatin 80 mg/d, or matching placebo at hospital discharge for 3 
to 4 years. Savchuk et al [7] increased the total coronary blood CK-MB 
activity by 57.3 + 11.7 mE/ml (p < 0.001) after induced short-term 
myocardial ischemia in dogs.  
Yang et al [8] decreased blood CK-MB levels and the 
markers of kidney injury by treatment with rhEpo (300 U/kg) 48 h 
after glycerol-induced rhabdomyolysis - one of the causes of acute 
renal failure - in rats. Popov et al [9] suggested that the risk allele (T) 
about 36% of homozygous genotype distribution in single-nucleotide 
polymorphism (SNP) rs1617640 at the promoter of the Epo gene 
plays a role in the development of renal dysfunction after cardiac 
surgery with cardiopulmonary bypass (CPB). Patients with the TT 
risk allele also associated with serum CK-MB levels increase (P=0.03), 
required more frequent acute renal replacement therapy. Wu et al 
[10] further increased the already significantly increased blood CK-
MB levels by Epo 300U/kg, IV administration after Escherichia coli 
lipopolysaccharide (20mg/kg) induced endotoxin shock in conscious 
rats. Cho et al [11] found the most frequent adverse events (AEs) by 
25% occurrences of elevated serum CK-MB levels in the rhEpo with 
albumin formulation administration over 32 hours than combined 
albumin-free rhEpo and existing rhEpo with albumin formulations in 
healthy male volunteers. Groopman JE [12] included the usage of 
hematopoietic growth factors, such as erythropoietin in alleviation of 
the zidovudine hematologic toxicity. Anemia, leukopenia and 
myopathy, also appears to be time and dose dependent. Patients 
often exhibit an associated elevation in CK-MB level. 
 
5. Conclusion 
Erythropoietin administration whether it interacted or not 
with reperfusion time kept short-term non significantly increased the 
predicted CK-MB values. Epo got on decline the CK-MB values from 
significant to non-significant levels proving an encouraging 
restorative short-term capacity, with interesting impacts in 
Cardiology.   
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